ArticleMikrochimica acta2026
Highly sensitive detection of species-specific malaria antigens using a cellulose nanobead-based lateral flow immunoassay.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Accurate and species-specific diagnosis of Plasmodium vivax malaria remains a significant challenge in malaria management due to the insufficient sensitivity and selectivity of existing rapid antigen tests. In this study, a highly sensitive and selective lateral flow immunoassay (LFIA) platform was developed utilizing blue-colored cellulose nanobeads (CNBs) as high-contrast colorimetric reporters for the detection of P. vivax lactate dehydrogenase (PvLDH). Six novel monoclonal antibodies with sub-nanomolar dissociation constants and exceptional specificity toward PvLDH were generated and characterized. Systematic screening identified an optimal antibody pair-clone #6 for detection (probe) and clone #4 for capture-which was subsequently incorporated into the CNB-based LFIA. The developed assay achieved limit of detection values of 5 ng/mL in buffer and 10 ng/mL in blood sample, representing a 50- to 100-fold improvement in sensitivity compared with conventional gold nanoparticle-based commercial RDTs. Notably, the distinct blue signal produced by the CNBs provided superior visual contrast against the red background of the blood sample, enabling clear, instrument-free interpretation. The assay exhibited no cross-reactivity with P. falciparum LDH or human LDH, thereby ensuring robust species-specific discrimination. Given its high sensitivity, portability, and strong performance in complex biological matrices, this CNB-based LFIA represents a promising next-generation point-of-care diagnostic tool for effective P. vivax malaria detection in endemic settings.
Indexed as
Identifiers
42295386What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.